LYT-200

Phase 1Small molecule

PPureTech

LYT-200 is one of 44 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeRecruiting

Myelodysplastic SyndromePhase 1

Recruiting

Competition

Competitive Landscape

49 competitors in Myelodysplastic Syndrome

#DrugCompanyPhaseTrials

Dacogen

Sun Pharmaceutical Industries, Inc.

Approved

42 2

Neoral

Novartis

Approved

10 3

Exjade

Novartis

Approved

5 4

Cytosar

Teva

Phase 3

40 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

56 6

Afinitor

Danocrine

Rocaltrol

Venclexta

Fludara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Recruiting·PPureTech·Phase 1·NCT05829226·90 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Completed·PPureTech·Phase 1/2·NCT04666688·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LYT-200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LYT-200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LYT-200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PureTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPureTech

LYT-200

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News